Plain-English translation of NCT05743049 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at the University of Pennsylvania are collecting blood samples from patients with pancreatic adenocarcinoma to study circulating biomarkers — tiny molecules in the blood that may help detect or monitor this disease. By analyzing these samples, scientists hope to discover new ways to diagnose pancreatic cancer earlier and better understand how the disease develops.
Pancreatic cancer is often diagnosed late because there are currently limited ways to detect it in its early stages. This research aims to identify blood-based biomarkers that could eventually lead to earlier detection and better treatment strategies for patients with pancreatic cancer.
You likely qualify if…
You likely don't qualify if…
You would have blood drawn during a visit at the University of Pennsylvania. The researchers will analyze your blood samples to look for specific biomarkers related to pancreatic cancer. This is an observational study, meaning you are not taking any new medications — just donating a blood sample to contribute to research that may help future patients.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Enrollment target
~30 participants
Started
February 2023
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liudmila Mazaleuskaya, PhD
Abramson Cancer Center, University of Pennsylvania
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.